HC Wainwright Forecasts Sight Sciences Q3 Earnings

Key Points

• HC Wainwright expects Sight Sciences to report a Q3 2026 loss of $0.08 per share and maintains a Buy rating with a $14 price target. Its estimates include losses of $0.40 per share for FY2026 and $0.24 for FY2027.
• Analyst sentiment is generally positive, with six Buy ratings, two Holds and one Sell; the stock has a consensus rating of Moderate Buy and an average price target of $9.00.
• Sight Sciences exceeded expectations in its latest quarter, reporting a $0.08-per-share loss versus the $0.18 consensus loss and revenue of $23.39 million. However, the company remains unprofitable, with a negative net margin of 35.69%, while hedge funds and institutions own 55.51% of the stock.

Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) - Investment analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Sight Sciences in a research note issued on Thursday, October 15th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Sight Sciences' current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Sight Sciences' Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.40) EPS and FY2027 earnings at ($0.24) EPS.

A number of other research analysts also recently issued reports on SGHT. Weiss Ratings restated a "sell (e+)" rating on shares of Sight Sciences in a research report on Friday, August 7th. UBS Group increased their price target on Sight Sciences from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Citigroup increased their price target on Sight Sciences from $8.00 to $10.00 and gave the stock a "neutral" rating in a research report on Monday, October 5th. Finally, Wall Street Zen upgraded Sight Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $9.00.

Sight Sciences Price Performance

NASDAQ:SGHT opened at $8.28 on Monday. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58. Sight Sciences has a twelve month low of $3.38 and a twelve month high of $9.71. The company has a market cap of $456.13 million, a PE ratio of -14.79 and a beta of 2.45. The company's 50 day moving average is $8.43 and its two-hundred day moving average is $6.10.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.10. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%. The company had revenue of $23.39 million for the quarter, compared to the consensus estimate of $21.72 million.

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Sight Sciences during the 2nd quarter worth approximately $16,710,000. Dimensional Fund Advisors LP grew its stake in shares of Sight Sciences by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company's stock valued at $1,288,000 after purchasing an additional 40,346 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Sight Sciences by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 293,358 shares of the company's stock valued at $1,106,000 after purchasing an additional 17,458 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Sight Sciences in the 2nd quarter valued at approximately $908,000. Finally, Bank of America Corp DE acquired a new position in shares of Sight Sciences in the second quarter valued at approximately $520,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Sight Sciences

In related news, CEO Paul Badawi sold 29,653 shares of Sight Sciences stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total transaction of $268,359.65. Following the transaction, the chief executive officer owned 6,092,819 shares in the company, valued at approximately $55,140,011.95. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James Rodberg sold 7,208 shares of the business's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $63,790.80. Following the transaction, the chief financial officer directly owned 216,829 shares in the company, valued at approximately $1,918,936.65. The trade was a 3.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 47,646 shares of company stock worth $429,157 over the last three months. 30.40% of the stock is owned by insiders.

About Sight Sciences

Sight Sciences, Inc is a medical technology company focused on developing and commercializing treatments for ophthalmic diseases. The company designs devices intended to address underlying causes of conditions such as glaucoma and dry eye disease, with an emphasis on less invasive procedures that can be performed in clinical settings.

Its product portfolio includes the OMNI Surgical System, a device used in minimally invasive glaucoma surgery to perform canaloplasty and trabeculotomy procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.